Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 14, 2025 08:00 ET | Source: Ultragenyx Pharmaceutical Inc.

Santé Canada étend l’approbation d’Evkeeza® (évinacumab) chez les enfants âgés d’à peine 6 mois atteints d’hypercholestérolémie familiale homozygote (HFHo)

TORONTO, 14 juill. 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ : RARE), une société biopharmaceutique spécialisée dans la mise au point et la commercialisation de nouveaux...
July 14, 2025 08:00 ET | Source: Ultragenyx Pharmaceutical Inc.

Health Canada Extends the Approval of Evkeeza® (evinacumab) to Children as Young as 6-months Old with Homozygous Familial Hypercholesterolemia (HoFH)

TORONTO, July 14, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialisation of novel therapies for rare and...
July 11, 2025 16:30 ET | Source: Ultragenyx Pharmaceutical Inc.

Ultragenyx Receives Complete Response Letter from FDA for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA)

Complete Response Letter (CRL) cited specific chemistry, manufacturing and controls (CMC) related observations that are resolvable FDA clinical reviews acknowledged that the clinical data are robust...
July 09, 2025 16:05 ET | Source: Ultragenyx Pharmaceutical Inc.

Ultragenyx and Mereo BioPharma Announce UX143 Phase 3 Orbit Study for Osteogenesis Imperfecta Progressing to Final Analysis

NOVATO, Calif., July 09, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) and Mereo BioPharma Group plc (NASDAQ: MREO), today announced that the randomized, placebo-controlled...
June 27, 2025 08:00 ET | Source: Ultragenyx Pharmaceutical Inc.

Ultragenyx Receives Breakthrough Therapy Designation for GTX-102 in Angelman Syndrome

Phase 3 Aspire study enrollment on track to complete in 2025 Aurora study to evaluate GTX-102 in other Angelman syndrome genotypes and ages expected to initiate later this year NOVATO, Calif., June ...
June 20, 2025 16:30 ET | Source: Ultragenyx Pharmaceutical Inc.

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

NOVATO, Calif., June 20, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...
June 03, 2025 17:00 ET | Source: Ultragenyx Pharmaceutical Inc.

Ultragenyx to Participate at Goldman Sachs 46th Annual Global Healthcare Conference

NOVATO, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...
May 20, 2025 17:00 ET | Source: Ultragenyx Pharmaceutical Inc.

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

NOVATO, Calif., May 20, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...
May 14, 2025 16:30 ET | Source: Ultragenyx Pharmaceutical Inc.

Ultragenyx Underscores Continued Commitment to Rare Disease Innovation with 2024 Impact Report

NOVATO, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) released its 2024 Impact Report today, which covers the company’s approach to corporate responsibility....
May 07, 2025 17:00 ET | Source: Ultragenyx Pharmaceutical Inc.

Ultragenyx to Participate at Bank of America’s 2025 Healthcare Conference

NOVATO, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...